cancer
The findings of a recent study suggest that antibiotics should be prescribed with caution in cancer patients who are planning to receive PD-1 inhibitors.
Results from a recent study suggest a correlation between the diversity and composition of the gut microbiota prior to transplantation and both the patient's survival and the probability of developing…
In a significant move to expand its immuno-oncology portfolio, Boehringer Ingelheim has acquired T3 Pharmaceuticals AG, a Swiss biotech company specializing in bacterial cancer therapy.
The findings of a recent study suggest that the composition of the mouth microbiota can be used to predict the recurrence of oral cancer.
The findings show that bacterial metabolites can sensitize cancer cells to treatment with immunotherapy by boosting the expression of HLA class I molecules.
Understanding how antibiotics influence the microbiota’s impacts on immunotherapy may inform strategies to identify cancer patients that are more likely to respond to cancer treatment.
MaaT033 (capsule), which is being developed as an adjunctive and maintenance therapy to improve overall survival in allo-HSCT, has received orphan drug designation (ODD) status from the European Medicines Agency…
The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.
Pedro Correa de Sampaio, Chief Executive Officer at Neobe Therapeutics, talks about the challenges to remove immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers.
The findings of a recent study suggest that targeting the interactions between MAdCAM-1 and specific receptors on the surface of immune cells may help to improve immunotherapy outcomes.
